Glycoproteins of NDV

NDV consists mainly of ribonucleoprotein and glycoproteins (haemagglutinin neuraminidase (HN) and fusion protein (F)) on its surface. These glycoproteins are mainly displayed as spines on the surface of the virus particle. Among them, HN has various functions such as increasing the adherence of tumor cells to lymphocytes, activating lymphocytes, and stimulating lymphocyte differentiation. The main function of the F protein is responsible for the fusion process between the viral vesicle membrane and the host cell membrane. The pathogenicity of NDV is closely related to two proteins. Recombinant vector vaccines based on the two protein genes of NDV are developed.

Fig.1 Structure of NDV. (Song, et al., 2019)

NDV Vaccine Development Service at CD BioGlyco

CD BioGlyco is experienced in Recombinant Glycoprotein Vaccine development. Vaccines are an effective means of combating NDV. The F protein and HN, the molecular basis of the virus, cause infection. We offer subunit vaccine development services for NDV.

We use molecular cloning technology to clone the HN and F antigenic protein genes of NDV into the plasmids. The expression plasmids are transferred to prokaryotic or eukaryotic cells to produce the HN and F antigenic proteins. This is subsequently purified and mixed with the appropriate Adjuvant to obtain subunit vaccines.

Further improvements in the production of subunit vaccines are needed to further increase immunogenicity, reduce immunization doses and manufacturing costs, etc. We will design the recombinant HN and F proteins to improve their immunogenicity.

Fig.2 Process of NDV vaccine development. (CD BioGlyco)

Applications

• Antibodies targeting HN and F proteins are protective. Our NDV vaccine development services include the production of HN and F proteins, which can be used for antibody development.
• The HN and F proteins we produce can be used for antiviral drug development, assay reagent development, and more.
• The HN and F proteins we produce can be used in the development of viral diagnostics.

Highlights of Us

• We have an integrated vaccine development system. We provide purity testing, microbiological testing, stability testing, etc.
• We have high-throughput expression and large-scale protein production capabilities. We shorten the time needed for vaccine development and improve accuracy through a variety of ways.

CD BioGlyco develops a wide range of Vaccines with high vaccine therapy. We aim to provide extensive help and support to our partners in vaccine development. Please feel free to contact us for more detailed information on vaccine development-related processes and quotes. We look forward to working with you.

Reference

1. Song, H.; et al. Application of Newcastle disease virus in the treatment of colorectal cancer. World J Clin Cases. 2019, 7(16): 2143-2154.